JADPRO

Proceedings of selected presentations from

2nd Annual Managing Hematologic Malignancies: The Balancing Act

Sandra Kurtin, RN, MS, AOCN®, ANP-C, University of Arizona and Arizona Cancer Center

Jean A. Ridgeway, MSN, APN, NP-C, AOCN®, University of Chicago Medical Center

Amy Goodrich, MSN, CRNP, John Hopkins Kimmel Cancer Center

Elizabeth Bilotti, MSN, RN, APN, OCN®, John Theurer Cancer Center, Hackensack University Medical Center

This activity is designed for oncology NPs, PAs, and CNSs interested in learning more about hematologic malignancies and the management of these patients.

This supplement provides 1.5 contact hours of continuing education credit.

This activity is jointly sponsored by Medical Education Resources, Inc., and Avid Education Partners, LLC.:

Supported by educational grants from Celgene, Cephalon Oncology, and Millennium: The Takeda Oncology Company.

Celgene

Continuing Education

Continuing Education Information

Editorial Commentary

Managing Hematologic Malignancies: The Balancing Act

Sandra Kurtin, RN, MS, AOCN®, ANP-C

Review Article

Current Approaches to the Diagnosis and Management of Myelodysplastic Syndromes

Sandra Kurtin, RN, MS, AOCN®, ANP-C

Review Article

Risk Stratification and Management of Acute Myeloid Leukemia

Jean A. Ridgeway, MSN, APN, NP-C, AOCN®

Review Article

Update on the Management of Follicular Lymphomas

Amy Goodrich, MSN, CRNP

Review Article

Management of Multiple Myeloma and Serious Side Effects

Elizabeth Bilotti, MSN, RN, APN, OCN®

Continuing Education

How to Claim Your Credit

Oral Mucositis: Addressing the Causes, Challenges, and Clinical Management

Carrie F. Daly, MS, RN, AOCN®, Rush University Medical Center

Annette M. Quinn, MSN, RN, University of Pittsburgh Medical Center

Oral mucositis remains one of the most painful and debilitating side effects of cancer therapy. A working knowledge of the risk factors for oral mucositis and oral cavity assessment protocols is essential to early identification of signs and symptoms in high-risk patients. The use of evidence-based guidelines and patient education will facilitate symptom management and supportive care strategies designed to avoid reductions, delays, or discontinuation of cancer treatment.

CE provided by:

Continuing Education